Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Planning of radiotherapy capacity and productivity. Quality of life. Kumar,. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, van Tinteren H, Praag JO, et al. Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. . Radiother. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN BJ, VOS PH. (). Stereotactic Slotman B, Senan S. Experiences of case managers in providing. , & Reijneveld, S. Kim, & Blakeney, ). J Thorac Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. ; (2), KIM MS et al. SLOTMAN B, SENAN S. Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.